Skip to page content
  • Immunotherapy for Chronic Liver Diseases


    Immunotherapy for Chronic Liver Diseases

    • Novel vaccination strategy against chronic liver diseases through stimulation of IMATEs with TLR9-L
    • IMATEs are an anatomic compartment within the liver tissue consisting of myeloid cells
    • iMATEs overcome regulatory cues that limit immune response during chronic liver infections
  • Small molecule hdac6 inhibitors


    Small molecule hdac6 inhibitors

    • ‍HDAC6 is a promising target for the treatment of chronic immune and inflammatory disorders such as rheumatoid arthritis (RA)
    • Marbostat are new small molecule inhibitors of HDAC6 with superior characteristics: in comparison to the established HDAC6 inhibitor Tubastatin A, the new inhibitors are more potent and specific, and most importantly they highly and selectively inhibit the enzyme activity of HDAC6 without destroying the protein.
    • Provision of a viable alternative to first line NSAIDs (non-steroidal anti-inflammatory drugs) in the treatment of RA

3 of 90 Tech Offers

Interested? Get in touch!

Contact a specific team member for individual topics via the Team section or simply use our contact form. You can also click on the button and drop us a line.